Media Coverage | Press From Trusted Sources

Migraine

Nerivio

December 10, 2024

2024

View All

Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage

The Nerivio® REN wearable is redefining pediatric migraine care as the only migraine-specific preventive therapy for children under the age of 12.

FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above

Children aged eight and up now have a prescribed non-drug option to treat migraine early and potentially prevent long-term disability and disease progression, addressing a critical unmet need in pediatric migraine care.

More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs

Following Colorado and Washington D.C., this expansion brings an additional seven million people into a new era of accessible and affordable non-drug migraine treatment.

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine.

Colorado Medicaid's Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment

Colorado Medicaid is the third federally-funded insurance plan to recognize the REN wearable as safe, effective migraine relief for adolescents and adults ages 12 years and older

DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine

This represents the second federally funded insurance plan, after the Veteran Administration (VA), to cover the innovative therapy.

Theranica's REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA

Highmark Inc. Publishes Commercial Coverage Policy for Nerivio®, a Drug-Free, Dual Use Treatment for Adolescents and Adults Living with Migraine

2023 Marks a Year of Phenomenal Progress for Theranica in Adolescent Migraine Care

Its Leading REN Wearable Device Brings Hope to Adolescents in the Fight Against a Leading Neurologic Disease

New Study Found Preventive Impact in Adolescents Who Frequently Used Nerivio® for Abortive Treatment of Migraine

New Frontiers in Pain Research Study Demonstrates a Reduction in Migraine Days in Teenagers Using the REN Wearable

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

Commercial Collaboration Follows News of Nerivio®'s Expanded CE Mark Approval as Novel Non-Drug, Dual-Use Migraine Treatment for Adolescents and Adults

First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting

Theranica to Unveil Groundbreaking New Real-World Data for Nerivio®, a Novel Drug-Free Device for Acute and Preventive Treatment of Migraine

New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine

Advances in Therapy Publishes Study Finding 12-Month Consistency in Utilization and Efficacy of Non-Drug, Non-Disruptive Wearable to Mitigate Migraine Burden

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Randomized Placebo-Controlled Study Published in Pain Management Evaluated the Preventive Efficacy of the Non-Drug Wearable As Early As After Two Weeks of Usage

Nerivio® CE mark indication expanded to preventive and acute treatment of migraine for adolescents and adults

The company is preparing to bring the wearable prescribed device to Europe next year

Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women

Controlled Retrospective Study Compared Use of Drug-Free Solution to Standard Care Treatments for Migraine During Pregnancy

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Nerivio Can Greatly Reduce Payer Expenses Through Reduction of Migraine Headache Days, Productivity Loss, and Healthcare Utilization Costs

Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents

Pediatric Neurology Publishes Study Demonstrating Value of Remote Electrical Neuromodulation (REN) Wearable for Young Adults with Migraine

Theranica's Nerivio® Cleared by FDA for Preventive Treatment of Migraine

Novel Prescription Wearable Proven Effective as a Preventive and Acute Treatment for Adolescents and Adults with Migraine

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India

The Theranica and Dr. Reddy's Laboratories agreement will bring Nerivio to millions of people with migraine in India

Pennsylvania-based Highmark Inc. Joins Theranica's Coverage with Evidence Program for Nerivio® Drug-Free Migraine Treatment Device

Members Will Receive Access to Theranica's Prescribed Wearable Device

Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device

Theranica's Evidence-Based Wearable Device will be Offered to Members Covered Under Harvard Pilgrim Health Care and Tufts Health Plan

Theranica Achieves Positive Results in Placebo-Controlled Pivotal Trial of Nerivio® for Preventive Treatment of Migraine

Remote Electrical Neuromodulation (REN) device Nerivio® demonstrates significant superiority over placebo, reduces mean number of migraine days per month when used every other day

New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines

Analysis of Clinical Trial Data Shows No Difference in Effectiveness Outcomes Between Use of Remote Electrical Neuromodulation (REN) Device Nerivio® and Tested Medications

Theranica Secures $45 Million Series C Funding Round

Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio® Financing Led by Philadelphia-Based New Rhein Healthcare, Selected Additional Co-Investors to Join Round at Final Closing

Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program

Nerivio is the First Migraine Treatment Device Offered to Costco Prescription Program Members

Peer-Reviewed Study Shows Positive Impact of Nerivio's® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response

Analysis Examined Nerivio's Remote Electrical Neuromodulation (REN) Migraine Treatment Augmented with its New In-App GIER Feature

Large Real-World Evidence Analysis Provides Comprehensive Evaluation of Nerivio® as an Effective Acute Treatment for Migraine

Largest peer-reviewed real-world study of a migraine device demonstrates that remote electrical neuromodulation (REN) provides a safe and effective drug-free acute treatment option for migraine sufferers

Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors

Former President and CEO of the Blue Cross Blue Shield Association, Serota Brings Decades of Experience in US Healthcare Leadership

Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine

Study shows remote electrical neuromodulation (REN) treatment provides relief for migraine headaches, offering a drug-free acute treatment option for people with chronic migraine

MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica's Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic

Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)

Granting of the Code Follows Continued Successful Clinical Trials of Nerivio in Adolescent Patients as well as those with Menstrual Migraine

Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents

Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation

Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache

20%-25% of women with migraine have menstrual migraine, which is typically associated with greater disability

Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US

Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents

Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans

Drug-Free Smartphone-Controlled Wearable Device Will Address Veteran Community, which has Higher Prevalence Migraine Compared to the General Population

FDA Approves Theranica's Nerivio® for Acute Treatment of Migraine in Adolescents

The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above

Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients

Clinical Evidence Supports Efficacy of Theranica's Prescribed Digital Therapeutic in Adult Chronic Migraine Patients

Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica's Nerivio® Device

Peer-Reviewed Post-Marketing Surveillance Study Tested Efficacy and Safety of Remote Electrical Neuromodulation (REN) in Acute Treatment of Migraine

Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021

Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

New Peer-Reviewed Article Publishes Results of Clinical Study Testing Efficacy of Remote Electrical Neuromodulation in Acute Treatment of Migraine in Chronic Migraine Patients

Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device

During Initial Limited Commercial Launch, Nerivio® Was Used more than 30,000 Times to Address Migraine Pain and other Symptoms

Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform

FDA-Authorized Drug-Free Migraine Treatment Device Available by Prescription through One-Stop Telemedicine Platform

Theranica Named to Fast Company's Annual List of the World's Most Innovative Companies for 2020

Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine, Recognized as a Leading Biotech Innovator

Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove

Cove Provides Rapid Consultation with a Licensed Physician and Home Delivery of the Novel FDA-Authorized Prescribed Wearable Device

Theranica Named 2020 'Game Changer' by CB Insights

BioMed Tech Developer Included in "Electro-Charged Therapeutics" Category Recognizing Companies Creating a Drug-Free Future

Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio™

Review Highlights Efficacy and Safety of Smartphone-Controlled Prescribed Wearable for the Acute Treatment of Migraine

Theranica's Nerivio™ Named in TIME's List of 100 Best Inventions of 2019

Acute Migraine Smartphone-Controlled Prescription Wearable Recognized in Health Care Category

Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production

Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable

Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

Headache Researchers in California and Missouri Conducted a Per-Patient Comparison of FDA-Cleared Wearable Device with Contemporary Usual Care

Theranica Appoints Senior Executives to Lead its New USA Subsidiary

New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio™ for Acute Treatment of Migraine

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

Theranica Raises $35M to Bring Innovative Migraine Device to the USA

aMoon leads round B of financing of the Israel-based company

OMRON VENTURES Joins Theranica's Series B Funding Round as Strategic Investor

Strategic investment signals positive response of healthcare community to Theranica's new approach to migraine management

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents

Theranica Raises $6M to Combat Migraine

Lightspeed leads round A of nancing in Israel-based advanced e-health company

Nerivio

View All

KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica

Soft Feel And Friendly To The Skin With Biocompatible TPE

News & Press

The Benefits ofDrug-free Migraine Management

From the News

Moving beyond one-dose-fits-all: How medtech and personalized dosing can improve outcomes

Wireless Nerivio Helps Manage Migraines

NewsInterview: The drug-free migraine treatment that’s got big pharma worried

Theranica aims to stretch FDA nod with study of neuromodulation device as preventive migraine treatment

Nerivio Gets FDA Nod for Use in Migraine Prevention

17-year-old finds miracle migraine treatment at Kansas City hospital

Press Releases

Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage

FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above

More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Colorado Medicaid's Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment

DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine

Theranica's REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA

2023 Marks a Year of Phenomenal Progress for Theranica in Adolescent Migraine Care

New Study Found Preventive Impact in Adolescents Who Frequently Used Nerivio® for Abortive Treatment of Migraine

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting

New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Nerivio® CE mark indication expanded to preventive and acute treatment of migraine for adolescents and adults

Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents

Theranica's Nerivio® Cleared by FDA for Preventive Treatment of Migraine

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India

Pennsylvania-based Highmark Inc. Joins Theranica's Coverage with Evidence Program for Nerivio® Drug-Free Migraine Treatment Device

Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device

Theranica Achieves Positive Results in Placebo-Controlled Pivotal Trial of Nerivio® for Preventive Treatment of Migraine

New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines

Theranica Secures $45 Million Series C Funding Round

Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program

Peer-Reviewed Study Shows Positive Impact of Nerivio's® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response

Large Real-World Evidence Analysis Provides Comprehensive Evaluation of Nerivio® as an Effective Acute Treatment for Migraine

Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors

Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine

MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica's Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic

Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)

Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents

Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache

Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US

Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans

FDA Approves Theranica's Nerivio® for Acute Treatment of Migraine in Adolescents

Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients

Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica's Nerivio® Device

Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device

Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform

Theranica Named to Fast Company's Annual List of the World's Most Innovative Companies for 2020

Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove

Theranica Named 2020 'Game Changer' by CB Insights

Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio™

Theranica's Nerivio™ Named in TIME's List of 100 Best Inventions of 2019

Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production

Theranica: New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

Theranica Appoints Senior Executives to Lead its New USA Subsidiary

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

Theranica Raises $35M to Bring Innovative Migraine Device to the USA

OMRON VENTURES Joins Theranica's Series B Funding Round as Strategic Investor

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

Theranica Raises $6M to Combat Migraine

KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica

Important Information

Indications For Use

Important Safety Information

Contraindications

The Benefits of
Drug-free Migraine Management